UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

CISPLATIN VERSUS CARBOPLATIN: COMPARATIVE REVIEW OF THERAPEUTIC MANAGEMENT IN SOLID MALIGNANCIES

Critical reviews in oncology/hematology, 2016-06, Vol.102, p.37-46

2016

Link zum Volltext

Verfügbarkeit prüfen

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Cochrane database of systematic reviews, 2020-01, Vol.1 (1), p.CD012988

2020

Link zum Volltext

Verfügbarkeit prüfen

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

Cochrane database of systematic reviews, 2018-04, Vol.2018 (4)

2018

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Cochrane database of systematic reviews, 2022-01, Vol.1 (1), p.CD013167

2022

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

Cochrane database of systematic reviews, 2018-11, Vol.2018 (11)

2018

Link zum Volltext

Verfügbarkeit prüfen

Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab

The American heart journal, 2009-08, Vol.158 (2), p.294-301

2009

Link zum Volltext

Verfügbarkeit prüfen

Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up

Current oncology (Toronto), 2023-01, Vol.30 (1), p.688-703

2023

Link zum Volltext

Verfügbarkeit prüfen

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

JNCI cancer spectrum, 2020-02, Vol.4 (1), p.pkz085

2020

Link zum Volltext

Verfügbarkeit prüfen

The buds and shoots of what I've grown to become: the development of reflective practice in Trainee Clinical Psychologists

Reflective practice, 2015-11, Vol.16 (6), p.777-789

2015

Link zum Volltext

Verfügbarkeit prüfen

Management of Aromatase Inhibitor Induced Musculoskeletal Symptoms in Postmenopausal Early Breast Cancer: A Systematic Review and Meta-analysis

Critical reviews in oncology/hematology, 2017-03, Vol.111, p.66-80

2017

Link zum Volltext

Verfügbarkeit prüfen

Shifting position: Reflections on becoming Shifting position: Reflections on becoming a clinical supervisor

Clinical psychology forum (Leicester, England : 2005), 2018-04 (304), p.14

Woodward, Natasha S

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of aromatase inhibitor-associated musculoskeletal symptoms: A systematic review

Journal of clinical oncology, 2016-01, Vol.34 (3_suppl), p.157-157

2016

Link zum Volltext

Verfügbarkeit prüfen

Letter to the editor: re Lu et al

Supportive care in cancer, 2021, Vol.29 (1), p.1-2

2021

Link zum Volltext

Verfügbarkeit prüfen

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Annals of oncology, 2019-05, Vol.30 (5), p.766-773

2019

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.602-602

2022

Link zum Volltext

Verfügbarkeit prüfen

Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer

Clinical breast cancer, 2018-10, Vol.18 (5), p.e1181-e1187

2018

Link zum Volltext

Verfügbarkeit prüfen

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Clinical breast cancer, 2019-06, Vol.19 (3), p.216-224

2019

Link zum Volltext

Verfügbarkeit prüfen

Predicting endocrine sensitivity in breast cancer

Pathology, 2021-07, Vol.53, p.S2-S2

2021

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

Investigational new drugs, 2020-12, Vol.38 (6), p.1815-1825

2020

Link zum Volltext

Verfügbarkeit prüfen

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b

British journal of cancer, 2018-11, Vol.119 (11), p.1316-1325

2018

Link zum Volltext

Verfügbarkeit prüfen

Development of novel biomarkers predictive of endocrine sensitivity in breast cancer

Pathology, 2020-02, Vol.52, p.S8-S8

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1071-1071

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (g BRCA1/2 )-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT071-CT071

2020

Link zum Volltext

Verfügbarkeit prüfen

Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia

Asia-Pacific journal of clinical oncology, 2022-06, Vol.18 (3), p.201-208

2022

Link zum Volltext

Verfügbarkeit prüfen

Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen

Journal of clinical pathology, 2017-11, Vol.70 (11), p.954

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(55)
Dissertationen
(1)

Sprache

Englisch
(56)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(36)
Humans
(20)
Female
(19)
Oncology
(16)
Breast Cancer
(11)
Breast Neoplasms - Drug Therapy
(10)
Middle Aged
(9)
Adult
(6)
Aged
(6)
Male
(6)
Breast Neoplasms - Pathology
(5)
Metastasis
(5)
Breast Neoplasms - Metabolism
(4)
Disease-Free Survival
(4)
Endocrine Therapy
(4)
Erbb-2 Protein
(4)
General & Internal Medicine
(4)
Medicine General & Introductory Medical Sciences
(4)
Medicine, General & Internal
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

CISPLATIN VERSUS CARBOPLATIN: COMPARATIVE REVIEW OF THERAPEUTIC MANAGEMENT IN SOLID MALIGNANCIES

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab

Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

The buds and shoots of what I've grown to become: the development of reflective practice in Trainee Clinical Psychologists

Management of Aromatase Inhibitor Induced Musculoskeletal Symptoms in Postmenopausal Early Breast Cancer: A Systematic Review and Meta-analysis

Shifting position: Reflections on becoming Shifting position: Reflections on becoming a clinical supervisor

Management of aromatase inhibitor-associated musculoskeletal symptoms: A systematic review

Letter to the editor: re Lu et al

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial

Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Predicting endocrine sensitivity in breast cancer

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b

Development of novel biomarkers predictive of endocrine sensitivity in breast cancer

Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial

Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (g BRCA1/2 )-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial

Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia

Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen

Suchergebnisse filtern